The report on the shift in R&D trends from small molecules to large molecules outlines the transformative changes in R&D paradigms. It highlights the increasing focus on biologics, such as monoclonal antibodies and gene therapies, which offer targeted and effective treatments for complex diseases.

Key sections discuss the scientific advancements facilitating this transition, the implications for pharmaceutical companies in terms of investment and regulatory strategies, and the R&D pipeline. Additionally, the report captures the impact of Off-patent drugs in the market, emphasizing the need for innovation in processes and technologies to support this shift.